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Reversal of EBV Immortalization
Precedes Apoptosis in IL-6±Induced
Human B Cell Terminal Differentiation
and terminal differentiation to plasma cells, which are
short-lived (Ho et al., 1986). Death of plasma cells is
tightly regulated to ensure the completion of terminal
differentiation and to effectively limit the synthesis and
secretion of immunoglobulins. Despite this understand-
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creases in immunoglobulin synthesis and secretion,Germany
development of the secretory apparatus, and reduction
of surface majorhistocompatibility complex (MHC) class
II expression (Raynal et al., 1989; Natkunam et al., 1994).
Summary Differentiation is temporally coupled to cell cycle arrest
resulting from activation of the cyclin-dependent kinase
Cell death in B cell terminal differentiation rapidly fol- (CDK) inhibitor p18INK4c (Guan et al., 1994; Morse et al.,
lows cell cycle arrest in IL-6 differentiation of EBV- 1997) and accumulation of hypophosphorylated retino-
immortalized, IgG-bearing human lymphoblastoid cells blastoma protein (pRB) (Morse et al., 1997). Cell death
in vitro. G1 arrest is now found to coincide with repres- rapidly follows cell cycle arrest (Morse et al., 1997).
sion of EBNA2 and LMP1, two EBV genes essential for These findings suggest that itmay be possible to investi-
B cell transformation, without activation of the viral gate the regulatory mechanism of cell death during B
lytic cycle. IL-6±differentiated B cells die by apoptosis, cell terminal differentiation in this model system in vitro.
as evidenced by increases in Annexin V binding activ- Studies of cultured human B lymphoblastoid cells
ity, PARP cleavage, and chromatin disorganization. must take into account the contributions of transforming
Expression of Mcl-1, a Bcl-2 family member, was spe- genes encoded by EBV, since lymphoblastoid cell lines
cifically induced during IL-6 differentiation and down- are indeed established by immortalization of resting hu-
regulated during apoptosis. Thus, IL-6 reverses EBV man B lymphocytes with EBV infection (Kieff, 1996).
immortalization and activates the terminal differentia- Eleven viral genes have been shown to be expressed
in latently infected B cells, of which at least five (EBNA1,tion program in IgG-bearing human B lymphoblastoid
EBNA2, EBNA-3A, EBNA-3C, and LMP1) are requiredcells, including regulation of an anti-apoptotic gene
for B cell transformation (Cohen et al., 1989; Ham-to coordinate differentiation, cell cycle arrest, and cell
merschmidt and Sugden, 1989; Kaye et al., 1993; Tom-death.
kinson et al., 1993). The expression of at least some
of these viral genes also protects B lymphocytes fromIntroduction
apoptosis (Gregory et al., 1991). EBNA2, together with
EBNA-LP, is the first viral gene expressed after infectionCell death is one of the primary mechanisms by which
(Allday et al., 1989; Rooney et al., 1989). It is thought tothehumoral immune response is regulated. It isessential
be essential for B cell transformation by activating G1-for the deletion of self-reactive B cell clones early in B
regulating proteins including cyclin D2 (Sinclair et al.,cell development (Goodnow, 1996). Apoptosis of acti-
1994; Kempkes et al., 1995). Studies of EBV mutantsvated B cells in germinal centers is known to be medi-
conditional for EBNA2 expression further suggest thatated by Fas signaling (Krammer et al., 1994; Nagata, 1997),
EBNA2 is required for both the initiation and the mainte-which can be countered by the interaction of CD40 on
nance of B cell transformation (Kempkes et al., 1995).
B cells with CD40 ligand on activated T cells (Bancher-
A transcriptional activator for viral and cellular genes,
eau et al., 1994), by B cell receptor signaling (Rothstein
EBNA2 regulates its own synthesis (Sung et al., 1991;
et al., 1995; Rathmell et al., 1996), and by the expression Woisetschlaeger et al., 1991; Rooney et al., 1992) as
of appropriate Bcl-2±family proteins (McDonnell et al., well as that of LMP1 (Abbot et al., 1990; Fahraeus et al.,
1989; Cory, 1995; Grillot et al., 1996). CD40 signaling, 1990; Wang et al., 1990; Zimber-Strobl et al., 1991) and
however, also activates the expression of Fas (Garrone down-regulates immunoglobulin heavy-chain gene ex-
et al., 1995; Rothstein et al., 1995; Schattner et al., 1995), pression (Jochner et al., 1996). LMP1 is an integral mem-
suggesting that apoptosis of B cells is determined at brane protein that shares significant sequence homol-
least in part by the balance between the dual functions ogy with the tumor necrosis factor (TNF) receptor and
initiated by CD40 signaling. The antigen-specific B lym- CD40 (Mosialos et al., 1995). Among the common target
phocytes undergo clonal expansion, affinity maturation genes activated by LMP1, TNF, and CD40 are the nu-
clear factor kB gene (Hammerskjold and Simurda, 1992)
and two prosurvival genes of the Bcl-2 family, A20 (La-§To whom correspondence should be addressed (e-mail: sckiang@
mail.med.cornell.edu. herty et al., 1992) and Bcl-2 (Henderson et al., 1991),
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although a lack of correlation between LMP1 and Bcl-2
expression has also been noted (Martin et al., 1993;
Fries et al., 1996). Regardless of whether Bcl-2 is a direct
target of LMP1 or not, constitutive LMP1 expression
has been shown to promote the survival of transformed
B cells in which the expression of EBNA2 is conditionally
shut off (Zimber-Strobl et al., 1996). Together with the
finding that LMP1 constitutively associates with TNF
receptor±associated proteins (TRAFs) (Devergne et al.,
1996), these results suggest that LMP1 transforms B
cells and protects them from apoptosis by constitutive
activation of a signaling pathway that converges with
those of TNF and CD40.
Induction of coordinated differentiation, cell cycle ar-
rest and cell death of human lymphoblastoid cells by
IL-6 suggests that IL-6 signaling may override immortal-
ization of B lymphocytes by EBV, thereby reactivating
the B cell terminal differentiation program. Alternatively,
death of EBV-immortalized B lymphoblastoid cells in
response to IL-6 may simply be a consequence of cyto-
kine activation of the viral lytic cycle. Here, we present
evidence suggesting that IL-6 induces cell death in ter-
minal differentiation of human lymphoblastoid cells by
repressing the EBV transforming genes without activat-
ing the lytic cycle, with apoptosis following cell cycle
arrest in G1.
Results
IL-6 Represses the Expression of EBV
Transforming Genes during B Cell
Terminal Differentiation
Cell death is temporally coupled to cell cycle arrest in
IL-6±induced terminal differentiation of the EBV-immor-
talized, clonal IgG1-bearing human lymphoblastoid CESS
cells (Morse et al., 1997). The cessation of cell cycle
progression suggests that IL-6 signaling in late stage B
cells may override immortalization of B cells by EBV.
This possibility was addressed by analysis of IL-6 regu-
lation of EBV transforming genes in CESS cells (Figure
1). IL-6 treatment simultaneously increases immuno-
globulin synthesis and reduces surface MHC class II
expression in 20%±30% of CESS cells (Natkunam et al.,
1994). The loss of surface MHC class II expression
allows differentiated cells (Ighi) to be enriched by nega-
tive selection with antibody to MHC class II conjugated Figure 1. IL-6 Represses EBNA2, LMP1, and EBNA1 Expression in
to magnetic beads (Morse et al., 1997). No EBNA2 pro- CESS Cells
tein was detected in differentiated cells (Ighi) by immu- (A) CESS cells cultured without (0) or with IL-6 for the number of
noblotting, in contrast to the high levels of Igg heavy days indicated or separated after 6 days of treatment with IL-6 into
differentiated (Ighi) and refractory (Iglo) cells by using HLA beadschain expressed (Figure 1A). The loss of EBNA2 expres-
were analyzed by immunoblotting for the expression of EBNA2,sion was specific to terminally differentiated cells; it was
LMP1, and EBNA1. The heavy chain of IgG is indicated (hIgg). NJBCnot detected in cells that failed to increase immunoglob-
T cells were used as a negative control. The molecular mass of each
ulin synthesis (Figure 1A, Iglo). LMP1 and EBNA1, two protein (kilodaltons) is indicated at right.
other EBV latent proteins, were similarly reduced in (B) CESS cells cultured without (2IL-6) or with IL-6 for 6 days (1IL-6)
IL-6±differentiated CESS cells (Ighi) but not in refractory or enriched for differentiated cells after IL-6 treatment (Ighi) were
stained for intracellular IgG (green) and intranuclear EBNA2 (red)cells (Iglo). Thus, cell cycle arrest and differentiation of
and counterstained with DAPI (blue) to localize the nucleus, andhuman B lymphoblastoid cells by IL-6 stimulation are
were analyzed by immunofluorescence microscopy. Arrowheads,accompanied by repression of EBV transforming genes.
differentiated cells that have lost EBNA2 expression.This observation was confirmed by immunocytochemi-
(C) CESS cells cultured without (2IL-6) or with IL-6 for 6 days (1IL-6)
cal analysis of the simultaneous expression of EBV and were stained for intracellular IgG (red) and LMP1 (green), and coun-
immunoglobulin genes at the single-cell level (Figures terstained with DAPI (blue). Arrowheads, differentiated cells that
have lost LMP1 expression.1B and 1C). CESS cells expressed a high but variable
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that enhanced immunoglobulin synthesis was accom-
panied by reduced LMP1 expression in LT-1/41-H1 cells
within 2 days of IL-6 treatment, although some of the
cells showed reduced LMP1 without increases in immu-
noglobulin (Figure 2B). As observed in CESS cells
(Morse et al., 1997), most IL-6±differentiated LT-1/41-
H1 cells were cell cycle arrested, as indicated by their
inability to incorporate bromodeoxyuridine (BrdU) (Fig-
ure 2C). Thus, it appears that coincidental with cell cycle
arrest and differentiation, IL-6 represses the expression
of EBV latent genes in terminal differentiation of IgG-
bearing human B lymphoblastoid cells.
Death of Terminally Differentiated B Cells Is Not
Caused by IL-6 Activation of EBV Lytic Cycle
Repression of EBV transforming genes is frequently as-
sociated with activation of viral lytic infection (Rochford
and Mosier, 1995). If the loss of EBNA2 expression is
followed by lytic infection, IL-6±differentiated cells would
die of cytopathic effects caused by viral lytic infection.
To address this possibility, the expression of EBV lytic
cycle genes in CESS cells was determined by Southern
blotting of RT-PCR (reverse transcriptase polymerase
chain reaction) products (Figure 3A). The marmoset B
lymphoblastoid cell line B95.8, which supports EBV rep-
lication in 25%±30% of the cells, served as a positive
control; the human NJBC T cells were used as a negative
control. IL-6 stimulation modestly increased the level
of BZLF1 transcripts encoding the Zebra protein (also
called Zta or EB1), which transactivates early EBV lytic
Figure 2. IL-6 Induces Cell Cycle Arrest and Represses EBNA2 and
genes (Figure 3A, 1IL-6). The increase in BZLF1 tran-LMP1 Expression in LT1/41-H1 Cells
scripts, however, was not specific to IL-6±differentiated
(A) Expression of intracellular IgG and intranuclear EBNA2 in LT1/
cells; it also was observed in refractory cells (compare41-H1 cells cultured without (2IL-6, open histograms) or with IL-6
Ighi with Iglo). (BZLF1 transcripts, present at a very lowfor 4 days (1IL-6, shaded histograms) was analyzed by flow cytome-
try as described in Experimental Procedures. level in untreated cells, were visible on the same blot
(B) LT1/41-H1 cells cultured without IL-6 (2IL-6) or with IL-6 for 2 after prolonged exposure.) The late gene BLLF1, which
days (1IL-6) were stained for intracellular IgG (red), LMP1 (green), encodes the envelope glycoprotein gp350/220, themost
and counterstained with DAPI (blue). Arrowhead, a differentiated
abundant viral protein expressed in the plasma mem-cell that has lost LMP-1 expression.
brane of lytically infected cells (Kieff, 1996), was not(C) LT1/41-H1 cells cultured without IL-6 (2IL-6) or with IL-6 for 2
expressed at all (Figure 3A).days (1IL-6) were labeled with BrdU for the last 25 hr and stained
for intracellular IgG (red), BrdU (green), andDAPI (blue).Arrowheads, Ectopic expression of Zebra has been shown to in-
two differentiated cells that did not incorporate BrdU. duce G1 arrest in epithelial cells (Cayrol and Flemington,
1996), raising the possibility that activation of Zebra by
level of EBNA2 in the nucleus and a low level of intracel- IL-6, albeit modest, may contribute to cell cycle arrest
lular IgG (2IL-6, Figure 1B). In response to IL-6, EBNA2 in differentiated CESS cells. This possibility was ad-
was markedly reduced in cells that were enhanced in dressed by immunostaining for simultaneous expres-
IgG synthesis, although some cells that lost EBNA2 ex- sion of Zebra and immunoglobulin (Figure 3B). Zebra
pression did not exhibit increased immunoglobulin syn- was expressed in an extremely low proportion of CESS
thesis (1IL-6). Analysis of differentiated cells (Ighi) after cells (1 in 5000 cells), and IL-6 treatment marginally
enrichment confirmed that all differentiated cells lost increased the proportion, to 3 in 5000 cells. However,
EBNA2 expression, in agreement with the immunoblot- there was no correlation between the expression of Ze-
bra and immunoglobulin in either the Ighi or the Iglo popu-ting results (Figure 1A). The LMP1 protein, which ap-
pears as a characteristic aggregated patch on the cell lations (Figure 3B). Given that 30%±40% of CESS cells
undergo cell cycle arrest in response to IL-6 (Morse etmembrane (2IL-6, Figure 1C), was similarly reduced in
IL-6±differentiated CESS cells (1IL-6). al., 1997) and all Ighi cells are arrested in G1, the expres-
sion of Zebra also does not correlate with cell cycleRepression of EBV transforming genes expression in
B cell terminal differentiation was not restricted to the arrest in IL-6±differentiated cells. In addition, the early
lytic antigen BMRF1 (EA) (Pearson et al., 1983; RoeckelIgG1-bearing CESS cells. IL-6 stimulation of LT-1/41-
H1 cells, another EBV-immortalized IgG-bearing human et al., 1987), which was readily detected in B95.8 cells,
also failed to be activated in differentiated cells (Figurelymphoblastoid cell line, led to increased IgG synthesis
in approximately 30% of cells and reduction of EBNA2, 3C). Thus, cell cycle arrest and death of terminally differ-
entiated B cells are not caused by IL-6 activation of EBVas determined by fluorescence-activated cell sorter
(FACS) analysis (Figure 2A). Immunostaining showed lytic cycle genes.
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Figure 4. The IL-6 Differentiated CESS Cells Retain the EBV Genome
(A) The EBV DNA in CESS cells cultured without (0) or with IL-6 and
separated into differentiated (Ighi) and refractory (Iglo) cells were
analyzed by Southern blotting using a 32P-labeled probe containing
the viral BamHI terminal repeat (TR) region.
(B) Ethidium bromide stained gel showing equal DNA loading. The
HindIII±BstEI±digested l DNA was used as a molecular size marker
(kilobases).
To confirm further that the viral lytic cycle was not
activated in CESS cells by IL-6 treatment, the levels of
viral DNA present in CESS cells during IL-6 differentia-
tion were quantified by Southern blotting, using as a
probe a BamHI restriction fragment corresponding to
the viral terminal repeats. Clearly, the EBV genome was
retained, but not amplified, in IL-6±differentiated CESS
cells (Figure 4). Together, these results exclude the pos-
sibility that repression of the EBV transforming genes
by IL-6 is due to a loss of the viral genome or leads to
activation of the lytic cycle in B cell terminal differenti-
ation.
Terminally Differentiated Cells Are G1 Arrested
and Rapidly Die of Apoptosis
Having eliminated EBV lytic infection as a cause of cell
death, we addressed the cellular mechanisms that un-
derlie the death of terminally differentiated B cells. The
cycling CESS cells were represented in theG0/G1 phase
(44%), the S phase (35%), and the G2/M phase (21%)
of the cell cycle (Figure 5A). The IL-6±differentiated cells,Figure 3. IL-6 Does Not Activate the EBV Lytic Cycle
however, were arrested in G1 prior to death, as indicated(A) RT-PCR and Southern blot analysis of BZLF1 and BLLF1 RNAs
in CESS cells cultured without IL-6 (2IL-6) or with IL-6 (1IL-6) and by the pronounced accumulation of diploid cells (82%)
enriched for differentiated (Ighi) or refractory (Iglo) cells. The DNA and the depletion of cells that were replicating DNA
fragments represent BZLF1 mRNA (270 bp); the unspliced tran-
(8%). These results are consistent with our previousscripts and the contaminating genomic DNA of BZLF1 (396 bp); the
observations that IL-6±differentiated cells are impairedBLLF1 mRNA (309 bp); andthe GAPDH mRNA(598 bp), which served
as a control. The B95.8 cells were used as a positive control for in pRB phosphorylation and DNA replication (Morse et
lytic infection, and the NJBC T cells were used as a negative control. al., 1997).
(B) Lack of correlation between Zebra expression and immunoglob- The possibility that apoptosis accounts for the deathulin synthesis. CESS cells cultured without (2IL-6) or with IL-6 for
of G1-arrested differentiated B cells was then examined6 days (1IL-6) were stained for intracellular IgG (red), intranuclear
by the Annexin V binding assay (Figure 5B). Annexin V,Zebra (green), and DAPI (blue). For each 5000 cells characterized,
1 cell expressed Zebra in untreated cells and 4 in IL-6-treated cells. a member of the annexin family of proteins, binds to
The B95.8 cells were used as a positive control. phosphatidylserine in a Ca21 dependent manner (Andree
(C) Lack of EA expression in CESS cells. CESS cells cultured without
et al., 1990). Membrane ruffling, one of the early events(2IL-6) or with IL-6 for 6 days were stained for intracellular IgG
in apoptosis, is accompanied by translocation of phos-(red), EA (Green) and DAPI (blue). In 5000 cells characterized, none
expressed EA. B95.8 cells were used as a positive control. phatidylserine from the inner leaflet to the outer leaflet
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Figure 5. The IL-6 Differentiated CESS Cells
Are G1 Arrested and Bind Annexin V
(A) The relative DNA content of CESS cells
cultured without IL-6 (2IL-6) or with IL-6 for
6 days and enriched for differentiated cells
(1IL-6) was analyzed by flow cytometry. The
chart at right summarizes the percentages
of 10,000 cells characterized that contain 2N
(G0/G1), between 2N and 4N (S), and equal
or greater than 4N (G2/M).
(B) Annexin V binding of CESS cells cultured
without IL-6 (2IL-6) or with IL-6 for 6 days
and enriched for differentiated cells without
further culturing (1IL-6, 0) or cultured for an
additional 12 hr in the presence of IL-6 (1IL-6,
12) was analyzed by flow cytometry as de-
scribed in the Experimental Procedures. The
percentages of 10,000 cells in each popula-
tion that bind Annexin V are indicated.
of the plasma membrane, which renders phosphatidyl- and CESS cells after Fas ligation (Figure 6B, lanes 1±4).
Although PARP cleavage was not detected in IL-6±serine accessible to Annexin V (Koopman et al., 1994;
Martin et al., 1995). As shown by FACS analysis, binding differentiated cells immediately after enrichment, it was
evident in cells within 24 hr after enrichment, as shownto Annexin V was observed in a small fraction of CESS
cells (11%) before IL-6 treatment (Figure 5B, 2IL-6). The by the conversion of PARP to its 85 kDa product (lanes
5 and 6). Together, the time-dependent increases inproportion of cells that bind Annexin V increased to 21%
in IL-6±differentiated, G1-arrested cells immediately Annexin V binding and PARP cleavage and the chroma-
tin disorganization strongly suggest that terminally dif-after enrichment (Figure 5B, 1IL-6, 0), to 49% by 12 hr
after enrichment (1IL-6, 12). Since IL-6±differentiated ferentiated B cells die of apoptosis.
CESS cells die within 48 hr of enrichment (Morse et al.,
1997), Annexin V binding activity is markedly increased IL-6 Regulates the Expression of Mcl-1 but Not
Other Members of the Bcl-2 Family duringbefore cell death.
Death of IL-6±differentiated cells was also accompa- B Cell Terminal Differentiation
Proteins of the Bcl-2 family are regulators of apoptosisnied by time-dependent chromatin disorganization and
morphological alteration. There were no apparent mor- triggered by a variety of stimuli. Alterations in the ratios
of anti-apoptotic to pro-apoptotic members of the Bcl-2phological differences between IL-6±differentiated cells
and untreated cells when examined by DAPI (4', 6'- family play a central role in controlling the survival of
cells (Reed, 1994; Yang E. et al, 1995). To address thediamino-2'-phenylindole dihydrochloride) staining and
differential interference contrast microscopy (Nomarski) potential contribution of Bcl-2±family proteins to B cell
apoptosis during IL-6±induced terminal differentiation,(Figure 6A, Ighi-0). However, by 24 hr after enrichment,
the chromatin of IL-6±differentiated cells had become the expression of several of these proteins was exam-
ined by immunoblotting using specific antibodies. Thedisorganized, assuming a hollow ringlike configuration,
and the cells had become elongated (Ighi-24). Although expression of the anti-apoptotic proteins (Bcl-2 and Bcl-
xL) and the related Bag-1 and of the pro-apoptotic pro-chromatin condensation has not been detected in IL-
6±differentiated CESS cells (data not shown), it is evi- teins (Bax and Bak) remained unchanged throughout
IL-6 treatment, in striking contrast to the prominent in-dent in apoptotic Jurkat cells similarly analyzed after
anti-Fas treatment (Figure 6A, bottom). While the nature creases in the Igg heavy and l light chains (Figure 7A).
The Bad protein was not detected (data not shown). Theof the ringlike chromatin configuration remains to be
investigated, these results suggest that the chromatin lack of regulation of Bcl-2±family genes by IL-6 was
confirmed independently by immunoblotting analysesof terminally differentiated B cells are disorganized in
the process of cell death. of differentiated (Ighi) and refractory (Iglo) cells after IL-6
treatment; no changes in Bcl-2±family proteins were de-To investigate further the possibility that IL-6±differenti-
ated cells die of apoptosis, we assayed for the cleavage tected in either population (Figure 5A).
By contrast, Mcl-1, an anti-apoptotic member of theof poly (ADP-ribose) polymerase (PARP) (Figure 6B).
PARP (116 kDa), a substrate for caspases activated in Bcl-2 family (Kozopas et al., 1993), was dynamically
regulated by IL-6 during B cell terminal differentiationapoptosis (Lazebnik et al., 1994; Nicholson et al., 1995)
was cleaved to generate an 85 kDa product in Jurkat (Figure 7). Two Mcl-1 proteins (41 and 37 kDa) have
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Figure 7. Mcl-1 Is Regulated in IL-6 Differentiation of B Cells
(A) The expression of immunoglobulin heavy chain (hIgg), l light
Figure 6. The IL-6 Differentiated CESS Cells Die by Apoptosis chain (hIgl), and Bcl-2±family proteins in CESS cells cultured with-
(A) Chromatin disorganization in IL-6±differentiated cells. CESS cells out (0) or with IL-6 (1IL-6) for the number of days indicated, or
cultured without (2IL-6) or with IL-6 (1IL-6) and enriched for differ- enriched for differentiated (Ighi) and refractory (Iglo) cells after 6 days
entiated (Ighi) cells without further culturing (0) or cultured for an of IL-6 treatment, was analyzed by immunoblotting. The molecular
additional 24 hr in the presence of IL-6 (24) were stained with DAPI mass of each protein (kilodaltons) is indicated at right.
to visualize the chromatin and viewed by differential interference (B) Mcl-1 expression decreases during apoptosis of differentiated
contrast microscopy (Nomarski) to examine the cell morphology. cells. The expression of Mcl-1 proteins in CESS cells cultured with
JURKAT cells undergoing apoptosis after cross-linking with anti- IL-6 (U), or after enrichment for differentiated (Ighi) and refractory
Fas antibodies were used as a reference. Arrowheads, chromatin (Iglo) cells without further culturing (0) or cultured for an additional
disorganization in CESS cells. 24 h in the presence of IL-6 (24), was analyzed by immunoblotting.
(B) PARP is cleaved in differentiated CESS cells that undergo The two Mcl-1 proteins are as marked. After densitometric scanning
apoptosis. CESS cells were cultured without or with IL-6 as indi- of radiographs, the amounts of the 41 kDa (filled bars) and the 37
cated. The IL-6±differentiated cells were enriched (Ighi) without fur- kDa (open bars) Mcl-1 proteins relative to IL-6±treated cells before
ther culturing (lane 5) or cultured for an additional 24 hr in the separation were plotted, as shown in the histogram.
presence of IL-6 (lane 6). As a control for PARP cleavage, apoptosis
was induced in JURKAT and in CESS cells by Fas ligation. The
migrations of PARP (116kDa) and its cleavage product (85 kDa) is
comparison to IL-6±treated cells before separation (Fig-marked.
ure 7B). The levels of the 41 kDa Mcl-1 protein in Ighi
cells, however, rapidly declined as the cells underwentbeen identified, and the smaller protein is believed to
apoptosis (Figure 7B). Consistent with a precursor±be a degradation product of the larger protein (Yang T.
product relationship, reduction in the 41 kDa proteinet al., 1995). Mcl-1 protein levels were elevated in CESS
was followed by a modest increase in the 37 kDa proteincells by day 2 of IL-6 stimulation (Figure 7A). Increases
(Figure 7B). This pattern of Mcl-1 regulation, and thein Mcl-1 proteins preferentially occurred in Ighi cells,
absence of changes in Bcl-2, Bcl-xL, Bax, Bad andsince the expression of both Mcl-1 proteins was mark-
edly higher in IL-6±differentiated, enriched cells (Ighi) in Bag-1, in IL-6±differentiated B cells suggest a unique
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role for Mcl-1 in terminal differentiation and apoptosis IgG-bearing lymphoblastoid cells. Previously, we showed
that most but not all G1-arrested cells exhibit increasedinitiated by IL-6.
immunoglobulin synthesis (Morse et al., 1997). Here we
show that, although all differentiated cells (Ighi) wereDiscussion
reduced in EBNA2 and LMP1 expression, some cells
that lack EBNA2 and LMP1 expression failed to increaseApoptosis of Terminally Differentiated
immunoglobulin synthesis (Figures 1 and 2). Thus, re-Plasma Cells
pression of EBV latent genes appears to be coupled toIn this study, we demonstrate that IL-6 signaling in IgG-
G1 arrest and not obligatorily to differentiation. Whatbearing human lymphoblastoid cells can override EBV
then is the relationship between repression of EBVimmortalization and reactivate the B cell terminal differ-
genes and cell cycle arrest? At least one of the EBVentiation program. Repression of EBV latent genes is
latent genes, EBNA2, can activate and maintain the cellan early event in response to IL-6, coincidental with cell
cycle progression through activation of G1-regulatingcycle arrest and preceding cell death. Since repression
cellular proteins such as cyclin D2 and CDK4 (Kempkesof EBV latent genes by IL-6 does not lead to activation
et al., 1995). Induction of G1-arrest by IL-6, however, isof the viral lytic cycle, death of B cells in IL-6±induced
not simply a reversal of cyclin and CDK activation.terminal differentiation is mediated by cellular mecha-
Rather, it results from activation of a CDK inhibitor p18nisms.
in the presence of sustained cyclin and CDK expressionIL-6±differentiated plasma cells die of apoptosis, as
(Morse et al., 1997). Repression of EBNA2 therefore cor-suggested by increases in Annexin V binding and PARP
relates with activation of p18 in IgG-bearing B lympho-cleavage, and by chromatin disorganization (Figures 5
blastoid cells. Ectopic expression of p18 was sufficientand 6). The mechanism that underlies the apoptosis of
to reconstitute cell cycle arrest in IgM-bearing B lym-terminally differentiated plasma cells, however, proba-
phoblastoid cells, in which IL-6 activated immunoglobu-bly differs from that of activated B cells in germinal
lin synthesis without disrupting the cell cycle (Morse etcenters. First, the expression of Bcl-2 and Bcl-xL are
al., 1997). Whether EBNA2 and p18 are independentlyknown toprotect germinal-center B cells from apoptosis
or sequentially regulated in IL-6 signaling isan important(McDonnell et al., 1989; Cory, 1995). By contrast, the
question that remains to be addressed.IL-6±differentiated cells died rapidly despite sustained
Repression of LMP1 expression is coincidental withexpression of Bcl-2, Bcl-xL, and Bag-1, and the lack of
G1 arrest and precedes apoptosis in terminal differentia-increases in Bax, Bak, and Bad (Figure 7A). Second,
tion of IgG-bearing cells (Figures 1 and 2). It did not,while the Fas receptor mediates apoptotic signals in
however, correlate with changes in Bcl-2, Bcl-xL, oractivated B cells in germinal centers (Nagata, 1997) as
Bag-1 (Figure 7), which are expressed even in apoptoticwell as in CESS cells before IL-6 treatment (Figure 6B),
cells (A. A. and C.-K., unpublished data). These resultsthe expression of Fas on CESS cells was profoundly
have two implications.reduced in response to IL-6 (A. A. and S. C.-K., unpub-
First, death of terminally differentiated plasma cellslished data). Third, apoptosis in most cells is mediated
must not occur before the completion of their physio-by activation of caspases such as CPP32 (Nicholson et
logic function: the production of antigen-specific immu-al., 1995; Faleiro et al., 1997). Despite cleavage of PARP
noglobulins. This suggests that in B cell terminal differ-(Figure 6B), CPP32 activity has not been detected in
entiation, there is a dynamic interplay between proteinsIL-6±differentiated CESS cells, although it can be readily
that inhibit apoptosis and those that promote apoptosis.activated by Fas ligation before IL-6 treatment (A. A.
Mcl-1 is a likely candidate for prolonging the survivaland S. C.-K., unpublished data). Finally, apoptosis was
of B cells in terminal differentiation. It is expressed ininduced by IL-6 in IgG-bearing lymphoblastoid cells but
germinal centers (Krajewski et al., 1995) and is believednot in IgM-bearing lymphoblastoid cells where enhanced
to be associated with the survival of peripheral humanimmunoglobulin synthesis was not accompanied by cell
B cells (Lomo et al., 1996). The expression of Mcl-1 hascycle arrest (Morse et al., 1997). This is in marked con-
been shown to delay but not to prevent cell death intrast to apoptosis of germinal-center B cells, which are
hematopoietic differentiation (Zhou et al., 1997). IL-6mostly IgM positive. Of interest, the IL-6±differentiated,
induced increases in Mcl-1 protein levels in IgG-bearingIgG-secreting plasma cells bear striking resemblance to
B cells in a time-dependent manner, coincidental withCD38hiCD20lo tonsillar plasmacytoid cells, which secrete
differentiation and preferentially in Ighi cells (Figure 7A).IgG and IgA but not IgM, die rapidly of apoptosis after
The subsequent decline in Mcl-1 expression in Ighi cells
isolation despite continuous expression of Bcl-2, and
during apoptosis (Figure 7B) is consistent with a role
do not express Fas (Merville et al., 1996). Together, our
for Mcl-1 in delaying, but not in preventing, apoptosis
results suggest that the IL-6±differentiated plasma cells
of B cells during terminal differentiation.
mimic the naturally occurring short-lived plasmacytoid
Second, these observations are reminiscent of the
cells present in germinal centers, and that the mecha-
lack of correlation observed by others (Martin et al.,
nism of plasma cell apoptosis is distinct from the Fas-
1993; Fries et al., 1996) between the expression of LMP1
dependent mechanism operating in B cell apoptosis.
and that of Bcl-2, Bcl-xL, and Bax, and suggest that the
survival of differentiated B cells in the absence of LMP1
Reversal of EBV Immortalization in Human may be mediated by other members of the Bcl-2 family.
B Cell Differentiation One candidate is Mcl-1, which clearly is activated by
Our results revealed that EBNA2, LMP1, and EBNA1 are IL-6, as discussed above. A second possibility is A20,
which is activated by both LMP1 (Laherty et al., 1992)coordinately silenced early during IL-6 differentiation of
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NaN3) and incubated with TBST containing 3% BSA (TBST/BSA) atand CD40 (Sarma et al., 1995). It is tempting to hypothe-
room temperature for 10 min. In all subsequent steps, TBST/BSAsize that repression of LMP1 leads to down-regulation
supplemented with 5% goat serum was used for antibody dilution,of A20 and ultimate apoptosis of IL-6±differentiated
and TBST was used for rinsing cells unless otherwise indicated. All
plasma cells despite theMcl-1 expression. This possibil- antibody incubations were performed at 378C for 40 min.
ity and the involvement of other genes in the coordina- Simultaneous staining of LMP1 and intracellular IgG was per-
formed as follows. Intracellular IgG was detected by incubation withtion of survival and apoptosis in Bcell terminal differenti-
affinity-purified polyclonal rhodamine-conjugated goat anti-humanation are under investigation.
IgG antibodies (1:400 dilution, Cappel/ICN); LMP1 was detected byExtensive investigations of EBV transforming genes
incubation with a mouse anti-LMP1 monoclonal antibody (1:100, CShave provided enormous insights into the mechanisms
1±4, Dako, Carpinteria, CA), followed by a brief rinse and incubation
that underlie the activation of the EBNA transcription with fluorescein isothiocyanate (FITC)±conjugated sheep anti-
unit (Jin and Speck, 1992) and the regulation of viral and mouse IgG antibodies (1:600, Cappel/ICN). For the detection of IgG
and EBNA2, intracellular IgG was stained as described above;cellular genes by EBNA2 and LMP1 (reviewed by Kieff,
EBNA2 was detected via a primary incubation with the rat mono-1996). By contrast, little is known about the mechanism
clonal antibody to EBNA2 (EBNA2-R3, 1:400 dilution) (Zimber-Stroblof repression of EBV transforming genes and its biologi-
et al., 1993), followed by a secondary incubation with a biotinylatedcal consequences in the life cycle of the virus and the
anti-rat IgG antibody (1:500, Amersham, Arlington Heights, IL), and a
development of B cell malignancy. Repression of EBV tertiary incubation with streptavidin conjugated to Texas Red (1:600,
latent genes has been alternatively associated (Roch- Amersham). Zebra protein was detected by using a mouse mono-
clonal anti-Zebra antibody (1:100, Dako), and EA was detected withford and Mosier, 1995) or not associated (Rochford et
a mouse monoclonal antibody directed against EA (1:200, Chemiconal., 1993) with activation of the viral lytic cycle in mice
International, Temecula, CA). Zebra and EA were revealed by subse-with severe combined immunodeficiency in vivo. In the
quent incubation with a sheep anti-mouse antibody conjugated topresent study, repression of EBV transforming genes
FITC (1:400, Cappel/ICN).
did not lead to activation of the lytic cycle in IL-6 differen- After incubation with the appropriate antibodies, the cells were
tiation of IgG-bearing B lymphoblastoid cells in vitro rinsed once with TBST for 10 min and counterstained with DAPI (17
mm in TBST, Boehringer Mannheim) for 10 min. After rinsing with(Figures 3 and 4). These results suggest that it may be
TBST (pH 8.4) for 10 min, the cells were sealed under coverslips inpossible to address the mechanism of repression of EBV
4-diazabicyclo(2,2,2) octane (2.5% w/v in glycerol, Sigma Chemical,latent genes in vitro by cytokine stimulation of clonal
St. Louis, MO). Visualization and photography were performed withhuman lymphoblastoid cell lines. Moreover, the failure
a Zeiss Axioplan 2 microscope.
to activate lytic genes following the shut-off of latent
genes in IgG-bearing human B lymphoblastoid cells may
BrdU Labeling and Detectionrepresent one of the mechanisms by which the propaga-
Simultaneous detection of intracellular IgG and BrdU was performedtion of EBV is restricted in secondary humoral immune
as previously described (Morse et al., 1997). Cells were cultured in
response. complete medium containing 10 mM BrdU (Sigma Chemical) for 24
hr in the presence or absence of IL-6. They were then collected,
rinsed, and stained for intracellular IgG (1:200 dilution) as describedExperimental Procedures
above. The stained cells were rinsed in TBST, denatured in 2 N HCl
at room temperature for 10 min, and neutralized in freshly preparedCells, IL-6 Treatment, and Separation of MHC Class
0.1 M sodium borate buffer (pH 8.5) at room temperature for 10 min.II±Positive and ±Negative Cells
The cells were then rinsed once with TBST and incubated in TBSTCESS and LT1/41-H1 are EBV-immortalized, IgG-bearing human B
containing 3% BSA for 15 min at room temperature to block cross-lymphoblastoid cell lines (Natkunam et al., 1994; Morse et al., 1997).
reactivity. The cells were incubated with a mouse anti-BrdU mono-B95.8 is a marmoset B cell line that has been infected with EBV
clonal antibody (1:500, Dako) at 378C for 40 min, followed by a 10-(Baer et al., 1984). JURKAT cells and NJBC cells (an IL-6±responsive
min rinse in TBST and incubation with an FITC-conjugated sheepderivative of the Jurkat T cell line) have been described (Hsu et al.,
anti-mouse IgG polyclonal antibody (1:600, Cappel/ICN) for 40 min1994). All cells were cultured in RPMI 1640 medium (Life Technolo-
at 378C. The cells were rinsed, counterstained, and sealed as de-gies, Frederick, MD) supplemented with 10% heat-inactivated fetal
scribed above.calf serum (Hyclone, Logan, Utah), 2 mM L-glutamine, penicillin (100
U/ml), streptomycin (100 U/ml), and 2 mM nonessential amino acids.
Recombinant human IL-6, synthesized in a baculovirus vector (May Flow Cytometry Analysis
et al., 1991), was added to some cultures (30 U/ml) for 6 days unless Staining for intracellular IgG and intranuclear EBNA2 was performed
otherwise indicated. The differentiated cells (high in intracellular IgG essentially as described (Akashi and Weissman, 1996). Cells were
with reduced surface MHC class II expression) were separated from washed twice with PBS buffer (pH 7.4) containing 1 mM MgCl2,
undifferentiated cells (low in intracellular IgG with high cell surface followed by fixation with 4% paraformaldehyde (w/v in PBS [pH 7.4])
MHC class II expression) by using anti-MHC class II antibodies for 5 min at 378C. The cells were washed twice with PBS containing
conjugated to magnetic beads (Dynal, Lake Success, NY) as pre- 0.1% BSA and permeablilized with PBS containing 0.1% BSA, 10
viously described (Morse et al., 1997). mM HEPES, and 0.3% saponin for 10 min at room temperature,
followed by washing with PBS containing 0.1% BSA. In all subse-
quent steps, antibodies were diluted in PBS containing 0.1% BSA,Immunofluorescence Microscopy
Immunofluorescence microscopy was performed essentially as de- 10 mM HEPES, and 0.03% saponin, and cells were incubated with
the diluted antibody on ice for 30 min. Intracellular IgG was detectedscribed (Morse et al., 1997). Cells, cultured in complete medium in
the presence or absence of IL-6, were collected and washed once with a FITC-conjugated anti-IgG polyclonal antibody (1:250 dilution,
Cappel/ICN); EBNA2 was detected by consecutive incubations withwith phosphate-buffered saline (PBS)/bovine serum albumin (BSA)
(137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.4 mM KH2PO4 [pH a rat monoclonal antibody (1:400, (Zimber-Strobl et al., 1993), a
biotinylated anti-rat antibody (1:600, Amersham), and R-phycoer-7.4], 1 mM MgCl2, 0.02% NaN3, and 1% BSA). Approximately 105
cells were spun onto a slide with a Cytospin centrifuge (Shandon, ythrin-conjugated streptavidin (1:600, PharMingen, San Diego, CA).
After incubation with the appropriate antibodies, the cells werePittsburgh, PA) at 200 rpm for 4 min and fixed in a freshly prepared
and chilled solution of methanol and glacial acetic acid (95:5) at washed twice with PBS/0.1% BSA and suspended in the same
buffer, and 10,000 cells were analyzed with a FACSCalibur (Becton-2208C for 30 min. The fixed cells were rinsed with TBST buffer (10
mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.02% Tween-20, and 0.02% Dickinson, San Jose, CA).
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Cell Cycle Analysis PARP (1:2000, Pharmingen, San Diego, CA). The bound antibody
was detected by ECL.Cell cycle analysis was performed as described (Quelle et al., 1993)
with the following modifications: 2 3 106 cells, either untreated or
differentiated with IL-6 and selected by HLA beads, were washed RNA Extraction and RT-PCR Analysis
RNA was isolated by the guanidine thiocyanate procedure as pre-once with PBS and incubated in 1 ml of a solution containing 50
mg/ml propidium iodide (Sigma Chemical), 0.1% Triton X-100, 0.1% viously described (Raynal et al., 1989). Total RNA from 3 3 105 cells
was used for oligo-dT-primed first-strand cDNA synthesis. Reversesodium citrate, and 1 mg/ml RNase A, for 30 min at 48C in the
dark. The DNA contents of each 10,000 cells were analyzed with a transcription was performed in a 20 ml volume containing 1 mg oligo-
dT (GIBCO±BRL); 0.5 mM dATP, dCTP, dGTP, and dTTP; 10 mMFACSCalibur with gating set to exclude debris and cells containing
DTT; and 400 U of Moloney murine leukemia virus reverse tran-less than diploid DNA.
scriptase (GIBCO±BRL). PCR analysis was performed by using 2 ml
of the cDNA solution in a buffer containing 0.4 mM deoxynucleotide
Annexin V Binding Assay triphosphates, 50 pmol of both the sense and the antisense oligonu-
The binding of annexin V to cell surface phosphatidylserine was cleotide primers (see below), 2.5 mM MgCl2 for amplification of
assayed on cells isolated by ficoll centrifugation and determined to BZLF1 and BLLF1 cDNA, and 2 mM MgCl2 for amplification of
be greater than 95% viable by trypan blue exclusion. Cells (5 3 105) GAPDH (glyceraldehyde 3-phosphate dehydrogenase) cDNA. The
were suspended in 1 ml of a binding buffer containing 10 mM samples were denatured at 948C for 7 min followed by amplifications
HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2. 190 ml of the for 25 cycles for BZLF1 and BLLF1 (30 s at 948C, 30 s at 568C, 1
cell suspension were incubated with 10 ml Annexin V-FITC (BioWhit- min at 728C) and 20 cycles for GAPDH (1 min at 948C, 1 min at 628C,
taker, Walkersville, MD) for 10 min at room temperature in the dark, 1 min at 728C). The reaction was held at 728C for 10 min. One fifth
washed and resuspended in the binding buffer and analyzed with of the RT-PCR products was analyzed by Southern blotting after
a FACSCalibur cell sorter. electrophoresis on a 2% agarose gel and transferred onto a nylon
membrane (Biotrans, ICN). The membrane was incubated in 63
SSC, 53 Denhardt, 0.05% sodium pyrophosphate, and 0.5% SDS
Immunoblotting Analysis
for 3 hr at 558C prior to hybridization overnight with a 32P-labeled
To detect the expression of EBNA2, LMP1, and EBNA1, cell lysates probe (see below) at the same temperature in a buffer containing
were prepared according to the method of Kempkes et al. (1995). 63 SSC, 13 Denhardt, 0.5% sodium pyrophosphate, and 100 mg/ml
In brief, cells (5 3 106) were washed once with PBS and lysed by salmon sperm DNA. The membranes were subsequently washed in
sonication in 25 mM Tris-HCl (pH 7.5), 25 mM EDTA, 5% glycerol, 1% 0.23 SSC, 0.5% SDS at 558C before autoradiagraphy.
(v/v) 2-mercaptoethanol, 1% sodium dodecyl sulfate (SDS), 0.1% The sequences of the oligonucleotides used were as follows:
bromophenol blue, 50 mM NaF, 5 mg/ml aprotinin, 1 mM phenylmeth- BZLF1 PCR primers: 59CCCAGTCTCGCACATAAC39 (Rochford and
ylsulfonyl fluoride (PMSF), 1 mg/ml leupeptin, and 100 mM sodium Mosier, 1995), 59GCCACCCGATTCTTGTATC39; hybridization probe:
vanadate. After centrifugation at 12,000 3 g for 5 min, the superna- 59CTAGTTCAGAATCGCATTCC39; BLLF1 PCR primers: 59CCTACC
tant was collected; proteins were quantifiedby the Bradford method; TTGAATACAACTGG39 (Kelleher et al., 1995), 59TGACGCTTGGCTG
and approximately 20 mg of proteins was loaded in each lane of GTGGTGC39; hybridization probe: 59TGGTGACATCCGCGGTGG
an 8% SDS-polyacrylamide gel. The proteins were separated via AT39; GADPH PCR primers: 59CCACCCATGGCAAATTCCATGGCA39,
electrophoresis (SDS±polyacrylamide gel electrophoresis [PAGE]) 59TCTAGACGGCAGGTCAGGTCCACC39; hybridization probe: 1.25
and transferred onto a nitrocellulose membrane, which was then kb PstI fragment containing the full-length rat cDNA (Raynal et al.,
blocked overnight with TBST (10 mM Tris [pH 8.0], 150 mM NaCl, 1989).
0.05% Tween-20) containing 5% non-fat milk. The antibodies used
for immunoblotting were a rat monoclonal antibody for EBNA2 Southern Blot Analysis
(1:200; EBNA2-R3, (Zimber-Strobl et al., 1993), a rat monoclonal Total DNA from 106 cells was extracted by resuspending cells in 10
antibody to EBNA1 (1:50; Zimber-Strobl et al., 1993), and a mouse mM Tris (pH 8), 1 mM EDTA, 0.2% SDS, 0.2 M NaCl, and 150 mg/ml
monoclonal antibody to LMP1 (1:100; CS1-4, Dako). The immunore- proteinase K. After incubation at 558C for 2 hr, two phenol/chloro-
active proteins were detected with a peroxidase-conjugated sec- form extractions, two chloroform extractions, and two ethanol pre-
ondary antibody and epichemiluminescence (ECL; Amersham, Ar- cipitations were performed successively. The DNA was then resus-
lington Heights, IL). pended in 100 ml of 10 mM Tris (pH 8), 1 mM EDTA, and 5 mg/ml
To determine the levels of expression of Bcl-2±family proteins, DNAse-free RNAse. Next, 20 ml of the DNA (z10 mg) was digested
cells were washed once in PBS and resuspended in a lysis buffer with BamHI, separated by agarose gel electrophoresis, and trans-
containing 20 mM HEPES (pH 7.0), 1 mM MgCl2, 10 mM KCl, 300 ferred onto a nylon membrane (Duralon, Stratagene). Prehybridiza-
mM NaCl, 0.5 mM dithiothreitol, 0.1% Triton X-100, 20% glycerol, tion was performed by incubating the membrane at 428C for 3 hr in
50 mM NaF, 5 mg/ml aprotinin, 1 mM PMSF, 1 mg/ml leupeptin, and 1% SDS, 23 SSC, 10% dextran sulfate, and 50% formamide. This
100 mM sodium vanadate. After a brief vortexing and incubation on was followed by hybridization with a 32P- labeled probe containing
ice for 10 min, lysates were collected by centrifugation at 14,000 3 the BamHI terminal repeat region of EBV, in the same hybridization
g for 5 min at 48C. Next, 20 mg of proteins was loaded onto each buffer except for the inclusion of 50 mg/ml of herring sperm DNA in
lane, resolved by 12% SDS-PAGE electrophoresis, and transferred the cocktail.
onto a nitrocellulose membrane. The expression of Bcl-2±family
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